肝动脉介入栓塞术治疗肝血管瘤患者疗效及血清GPDA、GP73和β2-MG水平变化*

doi:10.3969/j.issn.1672-5069.2020.06.037

摘要/Abstract

摘要： 目的探讨肝动脉介入栓塞术治疗肝血管瘤患者的疗效及血清甘氨酰脯氨酸二肽氨基肽酶(GPDA)、高尔基体蛋白73(GP73)和β2-微球蛋白(β2-MG)水平的变化。方法 2017年1月～2019年1月我院肝病科收治的60例肝血管瘤患者被随机分为介入手术组30例和开腹肝切除术组30例,分别接受经肝动脉介入栓塞术或开腹肝切除术。术后,随访半年。采用ELISA法检测血清GPDA、GP73、β2-MG水平及肿瘤坏死因子-α(TNF-α)、肿瘤特异性生长因子(TSGF)和甲胎蛋白(AFP)水平。结果介入手术组手术时间和术后住院时间分别为(84.7±21.9) min和(6.7±1.3)d,均显著短于开腹肝切除术组【分别为(126.8±60.5)min和(9.6±5.8)d,P<0.05】,术中出血量为(110.7±13.5)mL,显著少于开腹肝切除术组【(315.5±17.8)mL,P<0.05】;在术后1 w,介入手术组血清GPDA、GP73、β2-MG、TNF-α、TSGF和AFP水平分别为(62.6±9.8)U/L、(64.3±6.7)μg/L、(1.4±0.5)mg/L、(1.3±0.5)mg/L、(35.5±4.3)U/mL和(2.5±0.6)mg/L,均显著低于开腹肝切除术组【分别为(86.4±11.5)U/L、(112.2±9.3)μg/L,(2.3±0.9)mg/L,(2.1±1.2)mg/L,(61.3±9.8)U/mL和(4.7±0.8)mg/L,P<0.05】;介入手术组并发症发生率为13.3%,显著低于开腹肝切除术组(30.0%,P<0.05);在术后随访6 m,介入手术组总有效率为93.3%,显著高于开腹肝切除术组(80.0%,P<0.05)。结论采用肝动脉介入栓塞术治疗肝血管瘤患者疗效较好,且可降低血清GPDA、GP73、β2-MG、TNF-α和TSGF水平,明显改善围术期手术相关指标,减少并发症的发生,具有较高的临床安全性。

关键词: 肝血管瘤, 肝动脉介入栓塞术, 甘氨酰脯氨酸二肽氨基肽酶, 高尔基体蛋白 73, β2-微球蛋白, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of transhepatic artery embolization (TAE) in treatment of patients with hepatic hemangioma and serum glycylproline dipeptide aminopeptidase (GPDA), Golgi protein 73 (GP73) and β2-microglobulin (β2-MG) level changes. Methods 60 patients with hepatic hemangioma were treated in our hospital between January 2017 and January 2019, and 30 received TAE and another 30 underwent open hepatectomy. After operation, all patients were followed-up for six months. Serum GPDA, GP73, β2-MG, tumor necrosis factor-α (TNF-α), tumor-specific growth factor (TSGF) and alpha-fetoprotein (AFP) were assayed by ELISA. Results The operation time and postoperative hospital stay in TAE-treated patients were (84.7±21.9) min and (6.7±1.3) d, significantly shorter than [(126.8±60.5) min and (9.6±5.8) d, P<0.05], and bleeding during operation was (110.7 ± 13.5) mL, much less than [(315.5±17.8) mL, P<0.05] in those receiving open hepatectomy; 1 week after surgery, serum GPDA, GP73,β2-MG, TNF-α, TSGF and AFP levels in the interventional group were (62.6±9.8)U/L, (64.3±6.7)μg/L, (1.4±0.5)mg/L, (1.3±0.5)mg/L, (35.5±4.3)U/mL and (2.5±0.6)mg/L, all significantly lower than 【(86.4±11.5)U/L, (112.2±9.3)μg/L, (2.3±0.9)mg/L, (2.1±1.2)mg/L, (61.3±9.8)U/mL and (4.7±0.8)mg/L, respectively, P<0.05】 in patients receiving open hepatectomy; the incidence of complications after operation in the interventional group was 13.3%, which was obviously lower than that in the open hepatectomy group (30.0%, P<0.05); the total effective rate in the interventional group at six-month follow-up was 93.3%, which was obviously higher than that in the open hepatectomy group (80.0%, P<0.05). Conclusion The transhepatic artery embolization in the treatment of patients with hepatic hemangioma is efficacious, which might reduce serum GPDA, GP73 and β2-MG levels, and lead to less post-operational complications.

Key words: Hepatic hemangioma, Transhepatic artery embolization, Glycylproline dipeptide aminopeptidase, Golgi protein 73, β2-microglobulin, Therapy

王宸, 张雪斌, 程乐. 肝动脉介入栓塞术治疗肝血管瘤患者疗效及血清GPDA、GP73和β2-MG水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 905-908.

Wang Chen, Zhang Xuebin, Cheng Le. Efficacy of transhepatic artery embolization in treatment of patients with hepatic hemangioma[J]. Journal of Practical Hepatology, 2020, 23(6): 905-908.

参考文献

[1] 金震, 周晓春, 马红霞. 椎旁阻滞联合全身麻醉对肝血管瘤切除术患者疼痛及术后恢复的影响. 实用肝脏病杂志, 2019, 22(6): 908-911.
[2] Venkatram K, Sunil K B, Abhilash S, et al. Atypical exophytic liver mass: giant pedunculated hepatic haemangioma masquerading as a gastrointestinal stromal tumour of the gastric wall. SA J Radiol, 2019, 23(1): 1697-1698.
[3] Nassim F, Schlemmer H P, Friedhelm R, et al. CT and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome: a retrospective image review of 25 cases. PLoS One,2019, 14(2): 212-2186.
[4] Ju H L, Chang J Y, Young H K,et al. Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report. Clin Mol Hepatol, 2018, 24(2): 163-168.
[5] Guodong P, Zuyun D, Chunchun S, et al. Heterogeneity analysis of triphasic CT scan perfusion parameters in differential diagnosis of hepatocellular carcinoma and hemangioma. Medicine, 2018, 97(38): 12512-12513.
[6] 夏锋, 李雪松. 肝血管瘤诊断和治疗多学科专家共识(2019版). 中国实用外科杂志, 2019, 39(8): 761-765.
[7] Maria G, Gerald B, Alison K, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr,2016,5(3): 273-280.
[8] Zidan A, Ibrahim H, Farrag M, et al. Giant haemangioma of the liver with haemangiodudenal fistula: the first reported case in literature. Ann R Coll Surg Engl,2015, 97(6): 90-92.
[9] Igarashi G, Kenichiro M, Naoya S, et al. Interventional treatment for hepatic hemangioma accompanied by arterio-portal shunt with ascites. Intern Med, 2018, 57(19): 2847-2851.
[10] 闫军, 李亮. 腹腔镜肝血管瘤切除术患者术后感染相关因素分析. 实用肝脏病杂志, 2017, 20(3): 341-344.
[11] 殷杰, 徐新宝, 朱日祥. 腹腔镜肝切除术治疗肝血管瘤58例临床分析. 中华肝脏外科手术学电子杂志, 2018, 7(6): 469-472.
[12] Hiroyuki S, Yuki S, Shozo M, et al. Hepatic sclerosing hemangioma with predominance of the sclerosed area mimicking a biliary cystadenocarcinoma. Case Reports Hepatol, 2018, 20(1): 7353-7357.
[13] Umberto G R, Nicola C, Francesco P, et al. Spontaneous hepatic haemangioma rupture and hemoperitoneum: a double problem with a single stage interventional radiology solution. Clin Exp Emerg Med, 2019, 6(2): 169-172.
[14] Jingjun W, Ailian, Jingjing C, et al. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images. BMC Med Imaging,2019, 19(1): 23-24.
[15] Xin L, Chao A, Fangyi L, et al. The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study. BMC Cancer, 2019, 19(7): 550-551.
[16] Ryota K, Nozomi Mi, Yoshiaki M, et al. A hepatic sclerosing hemangioma emerged in the postoperative course of multiple gastric carcinoid tumors masquerading as metachronous liver metastasis. Int J Surg Case Rep,2019, 58(1): 1-5.
[17] Xiao F W, Bai X M, Wei Y, et al. Differentiation of atypical hepatic hemangioma from liver metastases: Diagnostic performance of a novel type of color contrast enhanced ultrasound. World J Gastroenterol, 2020,26(9): 960-972.
[18] Shaohong W, Jun G, Mengmeng Y, et al. Intratumoral coagulation by radiofrequency ablation facilitated the laparoscopic resection of giant hepatic hemangioma: a surgical technique report of two cases. Oncotarget, 2017, 8(31): 52006-52011.
[19] Li W, Li A, Wang B, et al. Automatic spectral imaging protocol and iterative reconstruction for radiation dose reduction in typical hepatic hemangioma computed tomography with reduced iodine load: a preliminary study. Br J Radiol, 2018, 91(1087): 978-981.
[20] Hara K, Fukumura Y, Saito T, et al. A giant cord hemangioma with extramedullary hematopoiesis and elevated maternal serum human chorionic gonadotropin: a case report and review of the literature. Diagn Pathol, 2015, 10(1): 154-155.
[21] Josephina A V, Manon B, Eleni L, et al. Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions. J Comput Assist Tomogr, 2018, 32(5): 750-756.
[22] Masaki W, Shigeyuki U, Mitsuyoshi T, et al. Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: report of a case. Int J Surg Case Rep, 2015,8(1): 137-140.
[23] 张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析. 实用肝脏病杂志, 2019, 22(5): 736-739.

肝动脉介入栓塞术治疗肝血管瘤患者疗效及血清GPDA、GP73和β2-MG水平变化^*

Efficacy of transhepatic artery embolization in treatment of patients with hepatic hemangioma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[2]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[3]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[4]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[5]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[6]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[7]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[8]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[9]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[10]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[11]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[12]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[13]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[14]	曾娇, 郭贵海. 聚乙二醇与乳果糖治疗肝性脑病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2021, 24(1): 99-102.
[15]	范静, 徐静, 袁雪. 利福昔明联合乳果糖治疗肝性脑病患者疗效及其血清S100B蛋白和神经元特异性烯醇化酶变化[J]. 实用肝脏病杂志, 2021, 24(1): 103-106.